Form 8-K

8-K — Aspire Biopharma Holdings, Inc.

Accession: 0001493152-26-036777

Filed: 2026-08-10

Period: 2026-08-06

CIK: 0001847345

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Unregistered Sales of Equity Securities

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.2 (ex10-2.htm)

EX-10.3 (ex10-3.htm)

EX-10.4 (ex10-4.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001847345

2026-08-06

0001847345

ASBP:CommonStockParValue0.0001PerShareMember

2026-08-06

0001847345

ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August

6, 2026

Aspire

Biopharma Holdings, Inc.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

23150

Fashion Drive, Suite 232

Estero,

Florida 33928

(Address

of Principal Executive Offices)

(908)

987-3002

(Registrant’s

Telephone Number)

194

Candelaro Drive, # 233

Humacao,

PR 00791

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.0001 per share

ASBP

The

Nasdaq Stock Market LLC

Warrants,

each exercisable for one share of common stock

ASBPW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01. Entry into a Material Definitive Agreement.

Purchase

Agreement

previously reported, in the Company’s Current Report on Form 8-K filed on June 12, 2026 (the “June 8-K”), Aspire Biopharma

Holdings, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with FireFish TopCo,

LLC (the “Seller”), pursuant to which (i) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company

agreed to purchase or cause certain of its Affiliates to purchase, all of the equity interests in certain of Seller’s subsidiaries

set forth in Annex C of the Purchase Agreement (the aforementioned equity interests, collectively, the ‘Transferred Equity

Interests”, and such subsidiaries, “Transferred Entities”), free and clear of all Liens, other than the Permitted Liens

and in accordance with the applicable Local Transfer Documents and (ii) the Seller agreed to sell, and cause the applicable Sellers to

sell, and the Company agreed to purchase, or cause certain of its affiliates to purchase, all of the assets of the other Business Entities,

as defined in the June 8-K, constituting the balance of the Business. The terms of the Purchase Agreement, and related consideration

are described in the June 8-K and are incorporated herein by reference. This Current Report on Form 8-K reports the closing of the Purchase

Agreement.

The

Purchase Agreement was previously filed as Exhibits 10.1 to the June 8-K and are incorporated herein by reference. The summary of the

terms of the Purchase Agreement in the June 8-K are subject to, and qualified in their entirety by, the full text of such documents including

the defined terms therein, which are incorporated herein by reference from the June 8-K.

Escrow

and Closing Agreement

August 6, 2026,

the Company and the Seller entered into an Escrow and Closing Agreement (the “Closing Agreement”), pursuant to which the

parties acknowledged and agreed that all conditions to the closing of the transactions contemplated by the Purchase Agreement (the “Closing”)

had been irrevocably satisfied or irrevocably waived by the party entitled to the benefit thereof, and that all Transaction Documents,

certificates and other deliverables required to effect the Closing (collectively, the “Closing Documents”) had been duly

executed and irrevocably delivered by the parties and were being held in escrow by the parties (or their respective counsel) pending

automatic release as described below.

Pursuant

to the Closing Agreement, the Closing Documents were automatically released from escrow without any further action, and the Closing

occured automatically and without any further action, immediately upon payment by the Company to the Seller of the Closing Purchase

Price in accordance with the closing statement delivered by the Seller to the Company on July 28, 2026 under the Purchase Agreement.

The

Company agreed to immediately pay the Closing Purchase Price to the Seller upon receipt of funds from its debt financing source (the

“Financing”). The Closing Agreement provides that the Financing is not, and was not, a condition to the Closing, that the

Seller entered into the Closing Agreement as an accommodation to the Company and without prejudice to the Seller’s rights (including

its right to terminate the Purchase Agreement pursuant to Section 9.01(c) or Section 9.01(e) thereof to the extent the Closing does not

promptly occur after July 31, 2026), and that the Company will use reasonable best efforts to obtain the Financing so as to enable it

to pay the Closing Purchase Price as promptly as possible.

The

foregoing summary of the Closing Agreement does not purport to be complete and is qualified in its entirety by reference to the full

text of the Closing Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein

by reference.

Working

Capital Financing Facility;

Note Purchase Agreement

July 31, 2026, the board of directors of the Company (the “Board”) adopted resolutions by written consent authorizing the

Company to issue convertible promissory notes (the “Notes”) pursuant to a Convertible Promissory Note Purchase Agreement,

dated as of August 6, 2026 (the “Note Purchase Agreement”), by and among the Company and the investors named therein

(the “Investors”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Investors Notes in

an aggregate principal amount of $3,750,000, for an aggregate purchase price of $3,000,000, reflecting an original issue

discount of 20% (the “Working Capital Transaction”). The proceeds of the Working Capital Transaction are intended

to provide additional working capital for the Company’s business and to allow for flexibility to pursue future growth opportunities

that the Company may identify in the future.

The Board ratified, confirmed, consented to and approved the Company’s

entry into the Purchase Agreement, and authorized the Company’s officers to negotiate, execute, deliver and perform the Note Purchase

Agreement and related ancillary documents, and to issue the Conversion Shares (as defined below) upon conversion of the Notes.

The

Notes are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Conversion Shares”),

in accordance with the terms of the Notes. The conversion price applicable to the Notes is $8.00 per share.

The

foregoing summary of the Note Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the

full text of the Note Purchase Agreement and the form of Note, copies of which are filed as Exhibit 10.3 and Exhibit 10.4, respectively,

to this Current Report on Form 8-K and are incorporated herein by reference.

RBW

Capital Partners LLC acted as exclusive financial advisor to the Company in connection with the foregoing transactions. Any securities

or brokerage services were offered through Dawson James Securities, Inc. RBW received a placement agency fee in the equal to 8% of the purchase

price and non-accountable expenses in the amount of 1%.

Item

2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The

disclosure set forth under Item 1.01 above regarding the Notes and the Note Purchase Agreement is incorporated herein by reference.

As described above, the Company issued Notes in an aggregate principal amount of $3,750,000 for

an aggregate purchase price of $3,000,000, reflecting

an original issue discount of 20%, pursuant to the Note Purchase Agreement. The proceeds of the

Notes are intended to provide additional working capital for the Company’s business and to allow for flexibility to pursue

future growth opportunities that the Company may identify in the future.

Item

3.02. Unregistered Sales of Equity Securities.

The

disclosure set forth under Item 1.01 above regarding the Notes and the Conversion Shares is incorporated herein by reference. The Notes,

and the Conversion Shares issuable upon conversion of the Notes, were offered and sold, and will be issued, in reliance on the exemption

from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule

506(b) of Regulation D promulgated thereunder, based on representations from the Investors that each is an “accredited investor”

as defined in Rule 501(a) of Regulation D, and in a transaction not involving a public offering and without any form of general solicitation

or general advertising.

Item

7.01 Regulation FD Disclosure.

August 10, 2026,

the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K.

The

information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section

18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that

section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as

amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

Exhibit

Number

Description

10.1*

Form

of Purchase Agreement, dated June 10, 2026, by and among Aspire Biopharma Holdings, Inc. and FireFish TopCo, LLC

10.2

Escrow and Closing Agreement, dated as of August 6, 2026, by and between FireFish TopCo, LLC and Aspire Biopharma Holdings, Inc.

10.3

Convertible Promissory Note Purchase Agreement, dated as of August 6, 2026, by and among Aspire Biopharma Holdings, Inc. and the Investors named therein.

10.4

Form of Convertible Promissory Note.

99.1

Press Release dated August 10, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

The schedules, exhibits or similar attachments have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The Company

will furnish copies of any schedules, exhibits or similar attachments to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K

to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

August 10, 2026

Aspire

Biopharma Holdings, Inc.

By:

/s/

Kraig T. Higginson

Name:

Kraig

T. Higginson

Title:

Chief

Executive Officer and Chairman

EX-10.2

Filename: ex10-2.htm · Sequence: 2

Exhibit

10.2

Agreement

THIS

AGREEMENT (this “Agreement”), effective as of July 31, 2026, is entered into by and among FireFish TopCo, LLC, a Delaware

limited liability company (the “Seller”), and Aspire Biopharma Holdings, Inc., a Delaware corporation (the “Purchaser”).

Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to such terms in the Purchase Agreement

(as defined below).

I T N E S S E T H:

WHEREAS,

Seller and Purchaser are parties to that certain Purchase Agreement, dated as of June 10, 2026 (as amended, the “Purchase Agreement”);

and

WHEREAS,

the parties desire to set forth their agreement regarding the escrow and release of all Transaction Documents to effect the Closing,

and regarding certain remedies available to Seller in the event Purchaser fails to consummate the Closing, upon the terms and subject

to the conditions set forth herein.

NOW,

THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the

receipt and sufficiency of which are hereby acknowledged, Seller and Purchaser hereby agree as follows:

SECTION

1. Satisfaction of Closing Conditions; Closing Documents in Escrow. The parties acknowledge and agree that all conditions

to the Closing of the Transactions contemplated by the Purchase Agreement have been irrevocably satisfied (or irrevocably waived by the

party entitled to the benefit thereof), and that all Transaction Documents, certificates or deliverables required or necessary to effect

the Closing or otherwise contemplated by the Purchase Agreement (including those to effectuate the Transactions in each of the jurisdictions

in which the Transferred Entities are organized) (collectively, the “Closing Documents”) have been duly executed and

irrevocably delivered by the parties and are being held in escrow by the parties (or their respective counsel), pending automatic release

as provided in Section 2 below.

SECTION

2. Automatic Release of Closing Documents; Deemed Closing. The Closing Documents shall be automatically released without any

further action from escrow, and the Closing shall be deemed to occur, automatically and without any further action, immediately upon

payment by Purchaser to Seller of the Closing Purchase Price in accordance with the Closing Statement delivered by Seller to Purchaser

on July 28, 2026 in accordance with the Purchase Agreement.

SECTION

3. Payment of Closing Purchase Price upon Receipt of Financing. Purchaser hereby agrees that it shall immediately pay the

Closing Purchase Price to Seller upon receipt of funds from its debt financing source (the “Financing”), it being

acknowledged and agreed that (i) the Financing is not, and was not, a condition to Closing, (ii) Seller has agreed to this Agreement

as an accommodation to Purchaser and without prejudice to its rights (including its right to terminate the Purchase Agreement pursuant

to Section 9.01(c) or Section 9.01(e) thereof to the extent the Closing does not promptly occur after the date of this Agreement), and

(iii) Purchaser will use reasonable best efforts to obtain funds from the Financing so as to enable it to pay the Closing Purchase Price

as promptly as possible; provided, however, that notwithstanding clause (ii) above, so long as Purchaser uses reasonable best efforts

to obtain the Financing and pays the Closing Purchase Price on or before 4:00 p.m. San Diego time by August 4, 2026 (the “Outside

Date”), Seller shall not, and shall cause its Affiliates not to, terminate the Purchase Agreement, assert any default, breach

or “intentional breach” under Section 9.02 of the Purchase Agreement, or seek any Reverse Termination Fee or other remedy,

in each case solely arising from the failure of the Closing to occur prior to such payment; provided further, that the Outside Date may

be extended for an additional five (5) Business Days at Seller’s sole discretion.

SECTION

4. Miscellaneous. This Agreement, together with the Purchase Agreement and the other Transaction Documents, constitutes the

entire agreement of the parties with respect to the subject matter hereof. This Agreement may be amended, restated, supplemented or otherwise

modified only by a written instrument signed by each of Seller and Purchaser, and no term or condition of this Agreement may be waived

except by a written instrument signed by the party against whom enforcement of such waiver is sought; no course of dealing or failure

or delay by any party in exercising any right hereunder shall operate as a waiver thereof. Without limiting the generality of the foregoing,

the provisions of Section 11.02 (Amendment and Modifications), Section 11.04 (Waiver), Section 11.05 (Notices), Section 11.09 (Governing

Law), Section 11.10 (Submission to Jurisdiction), Section 11.12 (Waiver of Jury Trial) and Section 11.13 (Counterparts) of the Purchase

Agreement are incorporated herein by reference, mutatis mutandis, provided that references therein to “this Agreement” shall

be deemed to refer to this Agreement.

[Remainder

of page intentionally left blank; signature page follows.]

WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first written above.

SELLER:

FireFish TopCo,

LLC

By:

Name:

Title:

PURCHASER:

Aspire Biopharma

Holdings, Inc.

By:

Name:

Title:

[Signature

page to Closing Agreement]

EX-10.3

Filename: ex10-3.htm · Sequence: 3

Exhibit 10.3

SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT

THIS

SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of August 6, 2026, is entered

into by and among Aspire Biopharma Holdings, Inc., a Delaware corporation (the “Company”), and the persons listed

on Schedule 1 attached hereto (each, an “Investor” and collectively, the “Investors”).

WHEREAS,

subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended

(the “Securities Act”), and Rule 506(b) promulgated thereunder, the Company and the Investors have agreed that the

Company will issue and sell to the Investors Convertible Promissory Notes, (the “Notes”), such form of Note attached

hereto as Exhibit A, convertible into capital stock of the Company further to the terms set forth in the Notes, all as more fully

set forth below.

WHEREAS,

the Notes carry an original issue discount of 20% (the “OID”), which is included in the principal balance of the Notes

such that the aggregate purchase price of the Notes is $3,000,000 and the aggregate principal amount of the Notes is $3,750,000; and

WHEREAS,

upon an Event of Default, as defined in the Notes, the principal amount of the Notes shall be convertible, at the option of the Investor,

into shares of the Company’s common stock as set forth in the Notes (such shares issuable upon conversion of the Notes being known

as the “Conversion Shares”).

NOW,

THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:

Sale and Issuance of the Notes. At the Closing (as defined below), the Company shall sell and issue to each Investor, and each

Investor shall purchase and acquire from the Company, upon the terms and conditions set forth herein, a Note in the original principal

amount and for the purchase price as is set forth on the Investor’s signature page to this Agreement. Each Investor’s obligations

hereunder pursuant to the transaction contemplated hereby shall be several, but not joint.

Closing of Sale of the Notes.

(a) The

closing with respect to the transactions contemplated hereby, shall take place remotely via the exchange of documents and signatures

simultaneously with the execution hereof (the “Closing”).

(b)

At the Closing, each Investor who shall purchase a Note hereunder shall deliver to the Company (i) an executed signature page to this

Agreement, completed and executed by such Investor, and (ii) payment by wire transfer for the purchase price of the Note to be purchased

by each such Investor, as set forth on such signature page.

(c)

As of the date of the Closing, the Company shall issue and deliver to each Investor an executed Note, substantially in the form of Exhibit

A attached hereto, in the original principal amount as is set forth on the signature page of such Investor delivered to the Company

hereunder and on Schedule 1 attached hereto opposite such Investor’s name. Each Investor shall be issued such Note upon

receipt by the Company of consideration that equals the purchase price of such Note, by wire transfer of funds, to the account designated

by the Company in accordance with this Agreement. The rights of each Investor with respect to such Investor’s Note shall be as

set forth in the Note and this Agreement.

Representations and Warranties of the Company to the Investors. The Company hereby represents and warrants to the Investors as

follows:

(a)

Organization, Good Standing and Qualification. The Company and each of its wholly- owned subsidiaries (the “Subsidiaries”)

has been duly incorporated, organized or formed and validly exists as a corporation or limited liability company in good standing under

the laws of the state of its incorporation, organization or formation. The Company and each of its Subsidiaries has all requisite power

and authority to carry on its business as it is currently being conducted and to own, lease and operate its properties. The Company and

each of its Subsidiaries is duly qualified to do business and is in good standing as a foreign corporation, partnership or limited liability

company in each jurisdiction in which the character or location of its properties (owned, leased or licensed) or the nature or conduct

of its business makes such qualification necessary, except, in each case, for those failures to be so qualified or in good standing which

(individually and in the aggregate) would not reasonably be expected to result in a material adverse change to (A) the business, condition

(financial or otherwise), results of operations, shareholders’ equity, properties or prospects of the Company or any of its Subsidiaries

(as hereinafter defined), taken as a whole; or (B) the ability of the Company to perform its obligations under this Agreement or consummation

of any of the other transactions contemplated by this Agreement (a “Material Adverse Effect”).

(b)

Authorization of this Agreement and the Notes. The execution, delivery and performance by the Company of this Agreement and the

Notes and of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of the Company.

Each of this Agreement and the Notes has been duly executed and delivered by the Company and constitutes a valid and binding obligation

of the Company, enforceable in accordance with its respective terms except as limited by applicable bankruptcy, insolvency, reorganization,

moratorium, fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally,

and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

(c)

Governmental Consents. All consents, approvals, orders or authorizations of, or registrations, qualifications, designations, declarations

or filings with, any governmental authority required on the part of the Company in connection with the execution of this Agreement and

the issuance of the Notes has been obtained.

(d)

Compliance with Laws. To its knowledge, the Company is not in violation of any applicable statute, rule, regulation, order or

restriction of any domestic or foreign government or any instrumentality or agency thereof with respect to the conduct of its business

or the ownership of its assets, the violation of which would materially and adversely affect the business, assets, liabilities, financial

condition or operations of the Company.

(e)

Compliance with Other Instruments. The Company is not in violation or default of any term of its Certificate of Incorporation

or Bylaws, as amended from time to time, or of any provision of any mortgage, indenture or contract to which it is a party and by which

it is bound or of any judgment, decree, order or writ, other than such violation(s) that would not have a material adverse effect on

the Company. The execution, delivery and performance of this Agreement and the Notes will not result in any such violation or be in conflict

with, or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument,

judgment, decree, order or writ or an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company

or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable

to the Company, its business or operations or any of its assets or properties.

(f)

Issuance of the Securities. The Notes are duly authorized and, when issued and paid for in accordance with the applicable provisions

herein and in the Notes, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.

The Conversion Shares, when issued upon conversion of the Notes, will be validly issued, fully paid and nonassessable, free and clear

of all liens or encumbrances imposed by the Company.

(g)

Capitalization. The capitalization of the Company is as set forth in its SEC Reports, as that term is defined below. The Company

has not issued any capital stock since its most recently filed periodic report under the Securities Exchange Act of 1934, as amended

(the “Exchange Act”) other than as set forth in its SEC filings, pursuant to the conversion of shares of the Company’s

Series A Convertible Preferred Stock issued under that certain Certificate of Designations, Preferences and Rights of the Series A Convertible

Preferred Stock of the Company, filed with the Secretary of State of the State of Delaware on February 2, 2026 (the “Series

A COD”), the exercise of awards under the Company’s equity incentive plans, the issuance of shares of Common Stock pursuant

to the Company’s incentive plans, the issuance of shares of Common Stock or Common Stock Equivalents pursuant to agreements outstanding

as of the date of the most recently filed periodic report under the Exchange Act. No person has any right of first refusal, preemptive

right, right of participation, or any similar right to participate in the transactions contemplated by the this Agreement or the Notes.

Except as set forth in its SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments

of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or

giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,

commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares

of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Notes or the Conversion

Shares will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any person (other than

the Investors) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset

price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary that contain

any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or

any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation

rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital

stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal

and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to

subscribe for or purchase securities.

(h)

SEC Reports; Financial Statements. Since December 31, 2025, the Company has filed all reports, schedules, forms, statements and

other documents required to be filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”)

and the Exchange Act (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being

collectively referred to herein as the “SEC Reports”). As of their respective dates, the Company believes that the

SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and that

none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to

be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,

not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting

requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements

have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the

periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto

and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects

the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations

and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(i)

Material Changes; Undisclosed Events, Liabilities or Developments. Other than as set forth in its SEC Reports, since the date

of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report

filed prior to the date hereof, to the best of the Company’s knowledge (i) there has been no event, occurrence or development that

has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities

(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with

past practice, and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed

in filings made with the SEC, (iii) the Company has not altered its method of accounting, and (iv) the Company has not declared or made

any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase

or redeem any shares of its capital stock.

(j)

Litigation. Except as set forth in its SEC Reports, there is no action, suit, notice of violation, proceeding or investigation,

inquiry or other similar Proceeding of any federal or state governmental authority pending or, to the knowledge of the Company, threatened

against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental

or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)

which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the Notes or the issuance of

the Notes or the Conversion Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in

a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the Company’s knowledge any director or officer thereof,

is or has been the subject of any Action involving the Company and a claim of violation of or liability under federal or state securities

Laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,

any investigation by the SEC involving the Company or any current or former director or officer of the Company. To the knowledge of the

Company, the SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the

Company or any Subsidiary under the Exchange Act or the Securities Act.

(k)

Compliance. Except as set forth in its SEC Reports, neither the Company nor any Subsidiary: (i) is in default under or in violation

of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company

or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is

in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or

any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree

or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance

or regulation of any governmental authority, including without limitation all foreign, federal, state and local Laws and regulations

relating to taxes, securities, environmental protection, occupational health and safety, product quality and safety, and employment and

labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

(l)

Intellectual Property.

(i)

Except as set forth in its SEC Reports, the Company owns or possesses or has the right to use pursuant to a valid and enforceable written

license, sublicense, agreement, or permission all Intellectual Property necessary for the operation of the business of the Company as

presently conducted, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. As used

in this Section 3(l), “Intellectual Property” means the following: (A) patent and patent Rights; (B) trademarks; (C)

copyrights, designs, data and database rights and registrations and applications for registration thereof; (D) inventions, invention

disclosures, statutory invention registrations, trade secrets and confidential business information, know-how, scientific and technical

information, data and technology, manufacturing and product processes, algorithms, techniques and analytical methodology, and research

and development information, whether patentable or nonpatentable, whether copyrightable or noncopyrightable and whether or not reduced

to practice; and (E) other proprietary rights relating to any of the foregoing.

(ii)

The Company has no knowledge that the Intellectual Property interferes with, infringes upon, misappropriate, or otherwise come into conflict

with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood

of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,

misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights

of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise

come into conflict with, any Intellectual Property rights of the Company, except in each case as could not have or reasonably be expected

to result in a Material Adverse Effect

(m)

Listing and Maintenance Requirements. Since February 3, 2026, the Company has not received notice from Nasdaq Capital Market (“Nasdaq”)

to the effect that the Company is not in compliance with the listing or maintenance requirements of Nasdaq. The Company is, and has no

reason to believe that it will not in the foreseeable future continue to be, in material compliance with all such listing and maintenance

requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company (“DTC”)

or another established clearing corporation and the Company is current in payment of the fees to the DTC (or such other established clearing

corporation) in connection with such electronic transfer. The Company is not subject to any “chill” issued by the DTC.

(n)

Offering. Assuming the accuracy of the representations and warranties of the Investors set forth herein, the offer, issue, and

sale of the Notes (and the Conversion Shares) are and will be exempt from the registration and prospectus delivery requirements of the

Securities Act, and have been registered or qualified (or are exempt from registration and qualification) under the registration, permit

or qualification requirements of all applicable state securities laws.

(o)

Knowledge. As used herein, the term “knowledge of the Company” (or similar language) shall mean the actual

knowledge of the executive officers and directors of the Company.

Representations and Warranties of the Investors to the Company. Each of the Investors, as to himself, herself or itself, represents

and warrants to the Company as follows:

(a)

The Investor is purchasing the Note, and if and when the Note is converted, will acquire the shares of the Company’s capital stock

issuable upon conversion thereof, in each case for investment for the account of the Investor and not for the account of any other person,

and not with a view toward resale or other distribution thereof. Such Investor understands that the Note being purchased by such Investor

has not been, and when issued, the shares of the Company’s capital stock issuable upon conversion thereof, will not be registered

under the Securities Act or applicable state securities laws and, therefore, cannot be resold unless they are subsequently registered

under the Securities Act and applicable state securities laws or unless an exemption from such registration is available. The Investor

further understands and agrees that, until so registered or transferred pursuant to the provisions of Rule 144 under the Securities Act,

that any stock certificate or, in the case of uncertificated securities, any notice of issuance, for the shares of the Company’s

capital stock issuable upon conversion thereof may bear the following legend:

“THE

SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),

AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED

FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT,

(II) IN COMPLIANCE WITH RULE 144, OR (III) PURSUANT TO AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION OR

COMPLIANCE IS NOT REQUIRED AS TO SAID SALE, OFFER OR DISTRIBUTION.”

(b)

The Investor is an “accredited investor” (as defined in Rule 501 of Regulation D under the Securities Act. Such Investor

or such Investor’s representative, during the course of this transaction and prior to the purchase of the Note being purchased

by the Investor hereunder, has had the opportunity to ask questions of and receive answers from representatives of the Company concerning

the terms and conditions of the offering of the Notes, and to obtain any additional information or documents relating to the Company,

its business and an investment in the Company necessary to verify the accuracy of information provided by the Company relating to the

business of the Company.

(c)

Such Investor or such Investor’s representative is capable of evaluating the merits and risks of the purchase of the Notes. Such

Investor has the capacity to protect his, her or its own interests in connection with the purchase of the Notes by reason of such Investor’s

preexisting personal or business relationship with the Company or its partners, officers, directors or controlling persons, or by reason

of such Investor’s business or financial experience or the business or financial experience of his, her or its representative (who

is unaffiliated with and who is not compensated by the Company or any affiliate, directly or indirectly).

Closing Conditions.

(a)

Conditions to Obligations of the Investors. It shall be a condition precedent to the obligations of the Investors hereunder to

be performed at the Closing that:

(i)

All representations and warranties of the Company shall be accurate, correct and complete on the date of the Closing.

(ii)

The Investors shall have received the duly executed Notes as set forth in Section 2(c) upon receipt by the Company from the Investors

of the consideration set forth opposite each Investor’s name on Schedule 1 attached hereto.

(iii)

The Company and each of its Subsidiaries shall have executed and delivered to the Investors such UCC-1 financing statements and other

instruments as are necessary or appropriate to perfect the security interest granted to the Investors under Section 10 of this Agreement

to secure the obligations under the Notes, which security interest shall be subordinate to any liens or security interests securing the

Company’s existing indebtedness that is secured as of the Closing Date.

(b)

Conditions to Obligations of the Company. It shall be a condition precedent to the obligations of the Company hereunder to be

performed at the Closing that:

(i)

All representations and warranties of the Investors shall be accurate, correct and complete on the date of the Closing.

(ii)

The Company shall have received the wire transfers described in Section 2 hereof in consideration of the issuance of the Notes.

(iii)

The Company shall have completed that certain acquisition of Dura Control Systems and its subsidiaries (the “Acquisition”),

on terms and conditions satisfactory to the Investors.

Registration of Conversion Shares.

6.1

Registration Procedures and Expenses. The Company shall:

(a)

As soon as practicable, but in no event later than 30 days after the Closing Date, prepare and file with the SEC a registration statement

on Form S-1 relating to the resale of the Conversion Shares by the Investors from time to time on the Nasdaq, or the facilities of any

national securities exchange on which the Common Stock is then traded or in privately-negotiated transactions (the “Resale Registration

Statement”).

(b)

Promptly prepare and file with the SEC such amendments and supplements to the Resale Registration Statement and the prospectus used in

connection therewith as may be necessary to keep the Resale Registration Statement effective until the earliest of (i) such time as all

of the Conversion Shares purchased hereunder have been sold pursuant to the Resale Registration Statement, or (iii) such time as the

Conversion Shares issued further to the Notes become eligible for resale without any volume limitations or other restrictions pursuant

to Rule 144 under the Securities Act without the requirement to be in compliance with Rule 144(c)(1).

(c)

Notwithstanding anything express or implied in this Agreement to the contrary, in the event that the SEC for any reason limits the number

of Conversion Shares that may be included and sold by the Investors in the Resale Registration Statement, the Company shall: (i) reduce

the number of Conversion Shares included in the Resale Registration Statement on behalf of the Investors in whole or in part (such portion

shall be allocated pro rata among such Investors) (such excluded Conversion Shares, the “Reduction Securities”), (ii)

give the Investors prompt notice of the number of such Reduction Securities excluded in connection with the exclusion of such Reduction

Securities arising from any interactions between the Company and the SEC with respect to the number of Conversion Shares that may be

included and sold by the Investors in the Resale Registration Statement, and (iii) use its commercially reasonable efforts at the first

opportunity that is permitted by the SEC to register for resale the Reduction Securities (or such portion thereof as the SEC will allow

to be registered for resale at such time) pursuant to a new registration statement covering the resale of the Reduction Securities (or

such portion thereof as the SEC will allow to be registered for resale at such time) for an offering to be made on a continuous basis

pursuant to Rule 415 and shall file such new registration statement with the SEC within thirty (30) calendar days following (x) the date

that the SEC would allow or permit such additional registration statement to be filed or (y) the date on which the Company first learned

the date that the SEC would allow or permit such additional registration statement to be filed, whichever of (x) or (y) is the later

date.

(d)

Furnish to the Investor with respect to the Conversion Shares registered under the Resale Registration Statement (and to each underwriter,

if any, of such Shares) such number of copies of prospectuses and such other documents as the Investor may reasonably request, in order

to facilitate the public sale or other disposition of all or any of the Conversion Shares by the Investor.

(e)

File documents required of the Company for normal Blue Sky clearance in states specified in writing by the Investor; provided,

however, that the Company shall not be required to qualify to do business or consent to service of process in any jurisdiction

in which it is not now so qualified or has not so consented.

(f)

Bear all expenses in connection with the procedures in paragraphs (a) through (f) of this Section 6.1 and the registration of

the Conversion Shares on behalf of the Investors pursuant to the Resale Registration Statement, other than fees and expenses, if any,

of counsel or other advisers to the Investors or underwriting discounts, brokerage fees and SECs incurred by the Investors, if any in

connection with the offering of the Conversion Shares on behalf of the Investors pursuant to the Resale Registration Statement.

6.2

Indemnification. For the purposes of this Section 6.2:

(a)

For the purpose of this Section 6.2: (i) the term “Investor/Affiliate” shall mean any affiliate of the Investor,

including a transferee who is an affiliate of the Investor, and any person who controls the Investor or any affiliate of the Investor

within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; and (ii) the term “Resale Registration

Statement” shall include any preliminary prospectus, final prospectus, free writing prospectus, exhibit, supplement or amendment

included in or relating to, and any document incorporated by reference in, the Resale Registration Statement referred to in Section

6.1.

(b)

The Company agrees to indemnify and hold harmless the Investor and each Investor/Affiliate, against any losses, claims, damages, liabilities

or expenses, joint or several, to which the Investor or Investor/Affiliates may become subject, under the Securities Act, the Exchange

Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation,

if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses

(or actions in respect thereof as contemplated below) (i) arise out of or are based upon any untrue statement or alleged untrue statement

of any material fact contained in (1) the Resale Registration Statement, including the Prospectus, financial statements and schedules,

and all other documents filed as a part thereof, as amended at the time of effectiveness of the Resale Registration Statement, including

any information deemed to be a part thereof as of the time of effectiveness pursuant to paragraph (b) of Rule 430A, or pursuant to Rules

430B, 430C or 434, of the Rules and Regulations, or (2) the Prospectus, in the form first filed with the SEC pursuant to Rule 424(b)

of the Regulations, or filed as part of the Resale Registration Statement at the time of effectiveness if no Rule 424(b) filing is required

or any amendment or supplement thereto; (ii) arise out of or are based upon the omission or alleged omission to state in any of them

a material fact required to be stated therein or necessary to make the statements in the Resale Registration Statement or any amendment

or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in light of the circumstances

under which they were made; or (iii) arise out of or are based in whole or in part on any inaccuracy in the representations or warranties

of the Company contained in this Agreement, or any failure of the Company to perform its obligations hereunder or under law, and will

promptly reimburse the Investors and each Investor/Affiliate for any legal and other expenses as such expenses are reasonably incurred

by the Investors or such Investor/Affiliate in connection with investigating, defending or preparing to defend, settling, compromising

or paying any such loss, claim, damage, liability, expense or action; provided, however, that the Company will not be liable

for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent

of the Company, which consent shall not be unreasonably withheld, and the Company will not be liable in any such case to the extent that

any such loss, claim, damage, liability or expense arises out of or is based upon (A) an untrue statement or alleged untrue statement

or omission or alleged omission made in the Resale Registration Statement, the Prospectus or any amendment or supplement thereto in reliance

upon and in conformity with written information furnished to the Company by or on behalf of the Investors expressly for use therein;

(B) the inaccuracy of any representation or warranty made by the Investors herein; or (C) any statement or omission in any Prospectus

that is corrected in any subsequent Prospectus that was delivered to the Investors prior to the pertinent sale or sales by the Investor.

(c)

Each Investor will severally, but not jointly, indemnify and hold harmless the Company, each of its directors, each of its officers who

signed the Resale Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities

Act or Section 20 of the Exchange Act, against any losses, claims, damages, liabilities or expenses to which the Company, each of its

directors, each of its officers who signed the Resale Registration Statement or controlling person may become subject, under the Securities

Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement

of any litigation, but only if such settlement is effected with the written consent of the Investor) insofar as such losses, claims,

damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i) the inaccuracy

of any representation or warranty made by the Investor herein; or (ii) any untrue or alleged untrue statement of any material fact contained

in the Resale Registration Statement, the Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission

or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Resale

Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto

not misleading in the light of the circumstances under which they were made, in each case under this clause (ii) to the extent, but only

to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Resale Registration

Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished

to the Company by or on behalf of the Investors expressly for use therein; and will reimburse the Company, each of its directors, each

of its officers who signed the Resale Registration Statement or controlling person for any legal and other expense reasonably incurred

by the Company, each of its directors, each of its officers who signed the Resale Registration Statement or controlling person in connection

with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided,

however, that each Investor’s aggregate liability under this Section 6 shall not exceed the amount of net proceeds

received by such Investor on the sale pursuant to the Resale Registration Statement of the Conversion Shares purchased by the Investor.

(d)

Promptly after receipt by an indemnified party under this Section 6.2 of notice of the threat or commencement of any action, such

indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 6.2 promptly

notify the indemnifying party in writing thereof, but the omission to notify the indemnifying party will not relieve it from any liability

that it may have to any indemnified party for contribution or otherwise under the indemnity agreement contained in this Section 6.2

to the extent it is not prejudiced as a result of such failure. In case any such action is brought against any indemnified party and

such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate

in, and, to the extent that it may wish, jointly with all other indemnifying parties similarly notified, to assume the defense thereof

with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action

include both the indemnified party, and the indemnifying party and the indemnified party shall have reasonably concluded, based on an

opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions

of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses

available to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party,

the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate

in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such

indemnified party of its election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying

party will not be liable to such indemnified party under this Section 6.2 for any legal or other expenses subsequently incurred

by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed such counsel in

connection with the assumption of legal defenses in accordance with the proviso to the preceding sentence (it being understood, however,

that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying

party, representing all of the indemnified parties who are parties to such action) or (ii) the indemnifying party shall not have employed

counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of

commencement of action, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying

party. The indemnifying party shall not be liable for any settlement of any action without its written consent. In no event shall any

indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have approved

in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld. No indemnifying party shall,

without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect

of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified

party from all liability on claims that are the subject matter of such proceeding, unless such settlement (x) includes an unconditional

release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims

that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or

a failure to act by or on behalf of any Indemnified Person.

(e)

If the indemnification provided for in this Section 6.2 is required by its terms but is for any reason held to be unavailable

to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c) of this Section 6.2 in respect

to any losses, claims, damages, liabilities or expenses referred to therein, then each applicable indemnifying party shall contribute

to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred

to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Investor from the

private placement of Notes hereunder or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such

proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but the relative fault of the

Company and the Investor in connection with the statements or omissions or inaccuracies in the representations and warranties in this

Agreement and/or the Resale Registration Statement that resulted in such losses, claims, damages, liabilities or expenses, as well as

any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Investor on the other

shall be deemed to be in the same proportion as the amount paid by the Investor to the Company pursuant to this Agreement for the Conversion

Shares purchased by the Investor that were sold pursuant to the Resale Registration Statement bears to the difference (the “Difference”)

between the amount the Investor paid for the Conversion Shares that were sold pursuant to the Resale Registration Statement and the amount

received by the Investor from such sale. The relative fault of the Company on the one hand and the Investor on the other shall be determined

by reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to

state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the

Company or by the Investor and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent

such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses

referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c) of this Section 6.2, any legal

or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions

set forth in paragraph (d) of this Section 6.2 with respect to the notice of the threat or commencement of any threat or action

shall apply if a claim for contribution is to be made under this paragraph (e); provided, however, that no additional notice

shall be required with respect to any threat or action for which notice has been given under paragraph (d) for purposes of indemnification.

The Company and the Investor agree that it would not be just and equitable if contribution pursuant to this Section 6.2 were determined

solely by pro rata allocation (even if the Investor were treated as one entity for such purpose) or by any other method of allocation

which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this Section

6.2, the Investor shall not be required to contribute any amount in excess of the amount by which the Difference exceeds the amount

of any damages that the Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission

or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall

be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Investor’s obligation

to contribute pursuant to this Section 6.2 are several and not joint with the Other Investors’ obligation to contribute

pursuant to Section 6.2 of the Agreements between the Other Investors and the Company.

6.3

Registration Delay Payments. If (i) the Resale Registration Statement is not filed with the SEC on or prior to the date required

under Section 6.1(a) (the “Filing Deadline”), (ii) the Resale Registration Statement is not declared effective by

the SEC on or before the date that is forty-five (45) calendar days after the Closing Date (or, in the event of a review or a comment

letter received in connection with the Resale Registration Statement by the SEC, seventy-five (75) calendar days after the Closing Date)

(the “Effectiveness Deadline”), or (iii) after its initial effective date, the Resale Registration Statement ceases for any

reason to remain continuously effective as to all Conversion Shares required to be included therein, or the Investors are otherwise not

permitted to utilize the Resale Registration Statement or any prospectus contained therein to resell the Conversion Shares, in each case

for more than ten (10) consecutive calendar days or an aggregate of fifteen (15) calendar days during any twelve (12)-month period (each

such event described in clauses (i) through (iii), a “Registration Default”, and the date on which such Registration Default

occurs, a “Registration Default Date”), then, in addition to any other rights the Investors may have hereunder or under applicable

law, the Company shall pay to each Investor an amount in cash, as partial liquidated damages and not as a penalty, equal to two percent

(2%) of the original principal amount of such Investor’s Note for the period from the Registration Default Date through the date

that is thirty (30) days thereafter, and an additional two percent (2%), compounding, of the sum of the original principal amount of

such Investor’s Note plus all liquidated damages previously accrued and unpaid under this Section 6.3 with respect to such

Note, for each successive thirty (30) day period (or portion thereof) thereafter until such Registration Default is cured, it being agreed

that there shall be no cap or maximum limit on the aggregate amount of liquidated damages payable under this Section 6.3. Such

liquidated damages shall be paid in cash to each Investor within five (5) business days after the end of each such thirty (30) day period.

The parties agree that the liquidated damages provided for in this Section 6.3 constitute a reasonable estimate of the damages

that will be suffered by the Investors by reason of a Registration Default and are not a penalty.

Reserved.

Miscellaneous.

Expenses. The Company shall pay its own expenses in connection with the transactions contemplated hereby, whether or not such

transactions shall be consummated, and shall reimburse the Investor for the reasonable legal fees and expenses of Lucosky Brookman LLP,

counsel to the Investor, in an amount of $25,000, which amount shall be payable at the Closing.

Waiver and Amendment. Any provision of this Agreement may be amended, waived or modified only by an instrument or writing signed

by the Company and the holders of at least a majority of the principal amount of the Notes then outstanding. Any amendment or waiver

affected in accordance with this Section 8(b) shall be binding upon the Company, the holders of the Notes and each permitted transferee

of a Note.

Binding Effect. The rights and obligations of the Company and the holder of this Agreement shall be binding upon and benefit the

successors, assigns, heirs, administrator and transferees of the parties.

Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. without

regard to the principles of conflicts of law of any other jurisdiction.

Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all

of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including

pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method

and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered

in construing or interpreting this Agreement.

Notices. Except as otherwise expressly provided herein, any notice required or permitted hereunder shall be given in writing and

it or any certificates or other documents delivered hereunder shall be deemed effectively given or delivered (as the case may be) upon

personal delivery (professional courier permissible) by electronic mail or facsimile (with written confirmation of receipt) or when mailed

by registered or certified United States mail, three (3) business days after deposit in the United States mail. Such certificates, documents

or notice may be personally delivered or sent to the following address: (i) if to the Investor, to the address listed on the signature

page hereto or to such other address which an Investor shall have given notice pursuant hereto to the Company, or, (ii) if to the Company,

to Aspire Biopharma Holdings, Inc.,23150 Fashion Drive, Ste 232, Estero, FL 33928.

Estero,

FL 33928, Attention: President, or to such other address of which the Company shall have given notice pursuant hereto; and a copy (which

shall not constitute notice) shall also be sent to Sichenzia Ross Ference Carmel, 1185 Avenue of Americas, 26th Floor, New

York, NY 10036.

Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall

be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall

be enforceable in accordance with its terms.

Number and Gender. Whenever used herein, the singular number shall include the plural and the plural shall include the singular,

and the use of any gender shall be applicable to all genders.

Entire Agreement. This Agreement, the Notes and other documents delivered pursuant hereto constitute the full and entire understanding

and agreement among the parties with regard to the subjects hereof and thereof and supersede any prior agreements (including any memorandum

of understanding, term sheet or letters of intent) between the parties regarding the subject matter hereof.

Attorneys’ Fees. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms

of this Agreement the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to

any other relief to which such party may be entitled.

Usury. If it shall be found that any interest, original issue discount or other amount deemed interest due under the Notes violates

the applicable law governing usury, the applicable provision shall automatically be revised to equal the maximum rate of interest or

other amount deemed interest permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it

will not seek to claim or take advantage of any law that would prohibit or forgive the Company from paying all or a portion of the principal

amount or interest, if any, due under the Notes.

Most Favored Nation. From the Closing Date until the date on which no principal, interest or other amounts remain outstanding

under the Notes, if the Company issues any debt or equity securities, or enters into any agreement (or amendment thereto) providing any

subsequent investor with terms that are more favorable in any material respect (including with respect to conversion price, interest

rate, original issue discount, security, covenants, events of default, redemption rights, registration rights or similar terms) than

the terms provided to the Investors under this Agreement or the Notes, the Company shall promptly, and in any event within three (3)

business days, notify each Investor of such more favorable terms, and, at each Investor’s election, such more favorable terms shall

be incorporated automatically into this Agreement and/or such Investor’s Note, as applicable, for so long as such more favorable

terms remain applicable to such subsequent investor. This Section 9 shall not apply to (i) any strategic transaction approved

by the Company’s board of directors that is not primarily undertaken for equity financing purposes, or (ii) issuances pursuant

to the Company’s equity incentive plans approved by its board of directors.

10.

Security Interest. As collateral for the full and timely payment and performance of the Company’s obligations under this

Agreement and the Notes, the Company hereby grants, and shall cause each of its Subsidiaries to grant, to each Investor a security interest

in substantially all of its assets, whether now owned or hereafter acquired. The Company shall, and shall cause each of its Subsidiaries

to, execute and deliver such UCC-1 financing statements and other instruments, and take such further action, as the Investors may reasonably

request to create, evidence and perfect such security interest. Such security interest shall be secured but subordinate in priority to

any liens or security interests securing the Company’s existing indebtedness that is secured as of the Closing Date.

[Signature

Page Follows]

WITNESS WHEREOF, the Company has executed this Convertible Promissory Note Purchase Agreement as of the date first above written.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

Name:

Title:

[See

Attached Investor Signature Pages]

WITNESS WHEREOF, the undersigned Investor has executed this Convertible Promissory Note Purchase Agreement as of the date first above

written, hereby authorizes the Company to append this signature page to a counterpart of this Convertible Promissory Note Purchase Agreement

as evidence thereof, and hereby subscribes for the purchase of a Note (as defined in this Convertible Promissory Note Purchase Agreement)

in the original principal amount specified below.

Original

Principal Amount of Note Subscribed For: ___________________

Purchase

Price of Note Subscribed For: ___________________

Acknowledged

and Accepted:

INVESTOR:

(Print

Full Name of Investor)

By:

Name:

Title:

(if

applicable)

Address:

Email:

[Signature

Page to Convertible Promissory Note Purchase Agreement –

Aspire

Biopharma Holdings, Inc.]

Schedule

of Investors

Name

Address

Principal

Amount of Notes

Exhibit

Form

of Secured Convertible Promissory Note

[See

attached]

EX-10.4

Filename: ex10-4.htm · Sequence: 4

Exhibit 10.4

NEITHER

THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE

HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED

FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES FILED PURSUANT

TO THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY

ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.

NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING

ARRANGEMENT SECURED BY THE SECURITIES.

Principal

Amount: $_______

Issue

Date: July ____, 2025

Purchase

Price with Original Issue Discount (“OID”): $_______

SECURED

CONVERTIBLE PROMISSORY NOTE

FOR

VALUE RECEIVED, Aspire Biopharma Holdings, Inc., a Delaware corporation (the “Borrower”), as of August

6, 2026 (the “Issue Date”), hereby promises to pay to the order of ___________ (the “Lender” and

including its registered assigns, the “Holder”), the principal sum of $_______ (the “Principal Amount”)

at maturity or upon acceleration or otherwise, as set forth herein (this “Note”). Upon an Event of Default, as such

term is defined herein, the then outstanding Principal Amount shall automatically increase by 20%.

This

Note is being issued by the Borrower to the Lender and other lenders pursuant to that certain Convertible Note Purchase Agreement (the

“Purchase Agreement”) entered into by the Borrower, the Lender, and such other lenders on the Issue Date.

The

maturity date of the Note shall be the date that is six (6) months from the Issue Date (the “Maturity Date,” as may

be extended as set forth below), and is the date upon which the Borrower shall pay to the Holder an amount in cash representing all then

outstanding Principal Amount and any other amounts outstanding pursuant to the terms of this Note. At the option of the Borrower, upon

prior ten (10) days’ prior written notice to the Holder, the Maturity Date may be extended by up to two (2) additional one-month

periods; each month extension will add an additional 5% to the OID (which shall automatically increase the then outstanding Principal

Amount by the same amount), which shall be calculated on a daily basis. By way of example only, should the Borrower extend the Maturity

Date one additional month, the OID on the Note shall be 25%, should it thereafter extend the Note for another additional month the OID

on the Note shall be 30%.

All

payments due hereunder (to the extent not converted into the Borrower’s Common Stock, par value $0.0001 per share (the “Common

Stock”)) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder

shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note. Whenever any amount expressed

to be due by the terms of this Note is due on any day which is not a business day, the same shall instead be due on the next succeeding

day which is a business day. As used in this Note, the term “business day” shall mean any day other than a Saturday, Sunday

or a day on which commercial banks in the city of New York, New York are authorized or required by law or executive order to remain closed.

This

Note is free from all taxes, liens, claims, and encumbrances with respect to the issue thereof and shall not be subject to preemptive

rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof. Capitalized

terms used in this Note shall have the meanings set forth in the Purchase Agreement unless otherwise defined in this Note.

This

Note is a secured obligation of the Borrower and is secured by a security interest in and continuing lien upon all assets and property

of the Borrower and each of its Subsidiaries, whether now owned or hereafter acquired, granted to the Holder pursuant to Section 10 of

the Purchase Agreement, which security interest is subordinate in priority to any liens or security interests securing the Borrower’s

existing indebtedness that is secured as of the Issue Date. The Borrower shall, and shall cause each of its Subsidiaries to, execute

and deliver such UCC-1 financing statements and other instruments, and take such further action, as the Holder may reasonably request

from time to time to create, evidence and perfect such security interest.

The

following additional terms shall also apply to this Note:

ARTICLE

1.1

Conversion Price. The conversion price shall be $8.00 per share of Common Stock (the “Conversion Price”). The

Conversion Price shall be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar

transaction that proportionately decreases or increases the Common Stock.

1.2

Conversion; Company Cash Payment Option.

(a)

Optional Conversion Right. The Holder shall have the right at any time to convert all or any part of the entire outstanding and

unpaid Principal Amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue

Date, or any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified

at the Conversion Price (a “Conversion”). The number of shares of Common Stock to be issued upon each such conversion

of this Note shall be determined by dividing the Conversion Amount (the portion of the Principal Amount being converted) by the applicable

Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the

“Notice of Conversion”), delivered to the Borrower by the Holder in accordance with Section 1.3 below; provided

that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in,

notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the “Conversion Date”).

(b)

Maximum Share Limitation. Notwithstanding the provisions of Section 1.2(a), in no event shall the Holder be entitled to convert

any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common

Stock beneficially owned by the Holder and its affiliates (excluding shares of Common Stock which may be deemed beneficially owned through

the ownership of the unconverted portion of this Note or the unexercised or unconverted portion of any other security of the Borrower

subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common

Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made,

would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock (the

“Maximum Share Amount”). The Holder, upon not less than 61 days’ prior written notice to the Borrower, may increase

the Maximum Share Amount, provided that the Maximum Share Amount shall never exceed 9.99% of the number of shares of Common Stock outstanding

immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder and the provisions

of this Section 1.2 shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered

to the Borrower. The Maximum Share Amount provisions of this paragraph shall be construed and implemented in a manner otherwise than

in strict conformity with the terms of this Section 1.2 to correct this paragraph (or any portion hereof) which may be defective

or inconsistent with the intended Maximum Share Amount provisions contained herein or to make changes or supplements necessary or desirable

to properly give effect to such limitation. The limitations contained in this paragraph shall apply to any successor holder of this Note.

For purposes of this Section 1.2, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), and Regulations 13D-G thereunder, except as otherwise provided

in clause (1) of such proviso.

(c)

Nasdaq 19.99% Cap. Notwithstanding anything to the contrary contained in this Note, Borrower and Holder agree that the total cumulative

number of shares of Common Stock issued to Holder hereunder together with all other Transaction Documents may not exceed the requirements

of Nasdaq Listing Rule 5635(d) (the “Nasdaq 19.99% Cap”). If the number of shares of Common Stock issued to Holder

reaches the Nasdaq 19.99% Cap, any remaining outstanding balance of this Note must be repaid in cash.

(d)

Change of Control Conversion. Notwithstanding the Holder’s right to convert this Note at any time pursuant to Section 1.2(a),

upon the occurrence of a Change of Control, the entire outstanding Principal Amount of this Note shall, at the election of the Holder

made by written notice to the Borrower at any time prior to the consummation of such Change of Control, automatically convert into shares

of Common Stock at the Conversion Price immediately prior to the consummation of such Change of Control, or, at the Holder’s election,

the Borrower shall prepay in cash the entire outstanding Principal Amount of this Note concurrently with the consummation of such Change

of Control. The Borrower shall provide the Holder with written notice of a proposed Change of Control not less than ten (10) business

days prior to the consummation thereof. For purposes of this Note, “Change of Control” means (i) the consummation

of a merger, consolidation, share exchange, business combination, reorganization or similar transaction involving the Borrower, unless

the persons who were the beneficial owners of the outstanding voting securities of the Borrower immediately prior to such transaction

beneficially own, immediately after such transaction, more than 50% of the outstanding voting securities of the surviving or resulting

entity, (ii) the sale, lease, exclusive license or other transfer, in one transaction or a series of related transactions, of all or

substantially all of the assets of the Borrower and its Subsidiaries, taken as a whole, to a person or group that is not an affiliate

of the Borrower, or (iii) the acquisition by any person or group (as defined under the Exchange Act) of beneficial ownership of more

than 50% of the outstanding voting power of the Borrower’s Common Stock, other than in a transaction approved in advance by a majority

of the Borrower’s board of directors as constituted immediately prior to such acquisition.

1.3

Authorized Shares. The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its

authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, equal to 150% of the number of shares

of Common Stock issuable upon the full conversion of this Note (the “Reserved Amount”). The Reserved Amount

shall be increased from time to time in accordance with the Borrower’s obligations hereunder. The Borrower represents that upon

issuance, such shares of Common Stock will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall

issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which this

Note shall be convertible at the Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there

shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of this Note.

The Borrower acknowledges that it has irrevocably instructed its transfer agent to issue certificates (or book-entry shares) for the

Common Stock issuable upon conversion of this Note, and agrees that its issuance of this Note shall constitute full authority to its

officers and agents who are charged with the duty of executing stock certificates (or applicable instructions for the issuance of book-entry

shares) to execute and issue the necessary certificates (or book-entry shares) for shares of Common Stock in accordance with the terms

and conditions of this Note.

If,

at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of

this Note; provided, that notwithstanding anything to the contrary herein, the Borrower shall only be required to confirm and adjust

the Reserved Amount one time per calendar month.

1.4

Method of Conversion.

(a)

Mechanics of Conversion. Subject to Section 1.2(b), this Note may be converted by the Holder further to Section 1.2(a)

in whole or in part at any time as described thereunder, (A) by submitting to the Borrower a Notice of Conversion (by facsimile, e-mail

or other reasonable means of communication dispatched on the Conversion Date prior to 11:00 a.m., New York, New York time) and (B) subject

to Section 1.4(b), surrendering this Note at the principal office of the Borrower.

(b)

Surrender of Note Upon Conversion. Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in

accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire

unpaid Principal Amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the Principal Amount

so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower,

so as not to require physical surrender of this Note upon each such conversion. In the event of any dispute or discrepancy, such records

of the Borrower shall, prima facie, be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing,

if any portion of this Note is converted as aforesaid, the Holder may not transfer this Note unless the Holder first physically surrenders

this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Holder a new Note of like tenor,

registered as the Holder (upon payment by the Holder of any applicable transfer taxes) may request, representing in the aggregate the

remaining unpaid Principal Amount of this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that,

by reason of the provisions of this paragraph, following conversion of a portion of this Note, the unpaid and unconverted Principal Amount

of this Note represented by this Note may be less than the amount stated on the face hereof.

(c)

Payment of Taxes. The Borrower shall not be required to pay any tax which may be payable in respect of any transfer involved in

the issue and delivery of shares of Common Stock or other securities or property on conversion of this Note in a name other than that

of the Holder (or in street name), and the Borrower shall not be required to issue or deliver any such shares or other securities or

property unless and until the person or persons (other than the Holder or the custodian in whose street name such shares are to be held

for the Holder’s account) requesting the issuance thereof shall have paid to the Borrower the amount of any such tax or shall have

established to the satisfaction of the Borrower that such tax has been paid.

(d)

Delivery of Common Stock Upon Conversion. Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or

other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section

1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for

the Common Stock issuable upon such conversion within two business days after such receipt (the “Deadline”) (and,

solely in the case of conversion of the entire unpaid Principal Amount hereof, surrender of this Note) in accordance with the terms hereof.

(e)

Obligation of Borrower to Deliver Common Stock. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed

to be the holder of record of the Common Stock issuable upon such conversion, the outstanding Principal Amount on this Note shall be

reduced to reflect such conversion, and, unless the Borrower defaults on its obligations under this Article I, all rights with

respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other

securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided

herein, the Borrower’s obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective

of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery

of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation

of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged

breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation

of the Borrower to the Holder in connection with such conversion. The Conversion Date specified in the Notice of Conversion shall be

the Conversion Date so long as the Notice of Conversion is received by the Borrower before 11:00 a.m., New York, New York time, on such

date.

(f)

Delivery of Common Stock by Electronic Transfer. In lieu of delivering physical certificates representing the Common Stock issuable

upon conversion, provided the Borrower is participating in the Depository Trust Company (“DTC”) Fast Automated Securities

Transfer (“FAST”) program, upon request of the Holder and its compliance with the provisions contained in Sections

1.2 and 1.3 and in this Section 1.4, the Borrower shall use its commercially reasonable efforts to cause its transfer

agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder’s Prime

Broker with DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system.

(g)

Failure to Deliver Common Stock Prior to Deadline. Without in any way limiting the Holder’s right to pursue other remedies,

including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of

this Note is not delivered by the Deadline the Borrower shall pay to the Holder $3,000 per business day for each business day beyond

the Deadline that the Borrower fails to deliver such Common Stock (unless such failure results from war, acts of terrorism, an epidemic,

or natural disaster) (“Conversion Default Payments”). Such amount shall be paid to Holder in cash by the fifth day

of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first

day of the month following the month in which it has accrued), shall be added to the Principal Amount of this Note on the fifth day of

the month following the month in which it has accrued, in which event such additional Principal Amount shall be convertible into Common

Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The

damages resulting from a failure, attempt to frustrate, and/or interference with such conversion right are difficult if not impossible

to quantify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(g) are justified.

1.5

Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless

(i) such shares are sold pursuant to an effective registration statement under the Securities Act of 1933 (the “Securities Act”),

or (ii) the Borrower or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance

and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be

sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold or transferred pursuant to Rule 144

under the Securities Act (or a successor rule) (“Rule 144”) or (iv) such shares are transferred to an “affiliate”

(as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section

1.5 and who is an “accredited investor” (as defined in Rule 501(a) of the Securities Act). Except as otherwise provided

(and subject to the removal provisions set forth below), until such time as the shares of Common Stock issuable upon conversion of this

Note have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number

of securities as of a particular date that can then be immediately sold, each certificate for shares of Common Stock issuable upon conversion

of this Note that has not been so included in an effective registration statement or that has not been sold pursuant to an effective

registration statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as

appropriate:

“THE

SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES

LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE

OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES

LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL,

IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.”

The

legend set forth above shall be removed and the Borrower shall issue to the Holder a new certificate therefore free of any transfer legend

if (i) the Borrower or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary for opinions

of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock may be made without registration

under the Securities Act, which opinion shall be accepted by the Borrower so that the sale or transfer is effected or (ii) in the case

of the Common Stock issuable upon conversion of this Note, such security is registered for sale by the Holder under an effective registration

statement filed under the Securities Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities

as of a particular date that can then be immediately sold.

1.6

Status as Shareholder. Upon submission of a Notice of Conversion by a Holder, (i) the shares covered thereby (other than the shares,

if any, which cannot be issued because their issuance would exceed such Holder’s allocated portion of the Reserved Amount or non-waived

Maximum Share Amount) shall be deemed converted into shares of Common Stock and (ii) the Holder’s rights as a Holder of such converted

portion of this Note shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and

to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Borrower to comply

with the terms of this Note. Notwithstanding the foregoing, if a Holder has not received certificates or transmission of such shares

pursuant to Section 1.4(f) for all shares of Common Stock prior to the tenth (10th) business day after the expiration of the Deadline

with respect to a conversion of any portion of this Note for any reason, then (unless the Holder otherwise elects to retain its status

as a holder of Common Stock by so notifying the Borrower) the Holder shall regain the rights of a Holder of this Note with respect to

such unconverted portions of this Note and the Borrower shall, as soon as practicable, return such unconverted Note to the Holder or,

if this Note has not been surrendered, adjust its records to reflect that such portion of this Note has not been converted. In all cases,

the Holder shall retain all of its rights and remedies (including, without limitation, (i) the right to receive Conversion Default Payments

pursuant to Section 1.4(g) to the extent required thereby for such conversion default and any subsequent conversion default and

(ii) the right to have the Conversion Price with respect to subsequent conversions determined in accordance with Section 1.1)

for the Borrower’s failure to convert this Note.

ARTICLE

PREPAYMENT

AND MANDATORY PAYMENT

2.1

Voluntary Prepayment. The Borrower may voluntarily repay all or any portion of the Principal Amount at any time without penalty.

2.2

Mandatory Payment. The Borrower shall prepay the outstanding Principal Amount in an amount equal to 25% of the net proceeds from

any equity or debt issuance concurrently with the receipt of such proceeds.

ARTICLE

III

EVENTS

OF DEFAULT

The

occurrence of any of the following shall each constitute an “Event of Default”, with no right to notice or the right to cure

except as specifically stated:

3.1

Failure to Pay. The Borrower fails to pay any amount when due on this Note, whether at the Maturity Date, upon acceleration, or

otherwise.

3.2

Reserve/Issuance Failures. The Borrower fails to reserve a sufficient amount of shares of Common Stock as required under the terms

of the Purchase Agreement, fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not

honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of any

securities of the Borrower held by the Holder, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in

certificated form) shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to any securities of the Borrower

held by the Holder as and when required by such securities, the Borrower directs its transfer agent not to transfer or delays, impairs,

and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) shares of Common Stock to be

issued to the Holder upon conversion of or otherwise pursuant to any securities of the Borrower held by the Holder as and when required

by such securities, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent

from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any shares of Common Stock

issued to the Holder upon conversion of or otherwise pursuant to any securities of the Borrower held by the Holder as and when required

by such securities (or makes any written announcement, statement or threat that it does not intend to honor the obligations described

in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations

shall not be rescinded in writing) for two business days after the Holder shall have delivered an applicable notice of conversion or

exercise. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default

of this Note, if a conversion of any securities held by the Holder is delayed, hindered or frustrated due to a balance owed by the Borrower

to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower’s transfer agent in order

to process a conversion or exercise (excluding for the avoidance of doubt, the conversion price which is the Holder’s obligation

to pay), such advanced funds shall be paid by the Borrower to the Holder within five business days, either in cash or as an addition

to the balance of this Note, and such choice of payment method is at the discretion of the Borrower.

3.3

Breach of Covenants. The Borrower breaches any covenant or other term or condition contained in this Note or any other documents

entered into between the Borrower and the Holder the breach of which has (or with the passage of time will have) and such breach is not

cured within five (5) business days of the date of such breach, if such breach is capable of cure.

3.4

Breach of Representations and Warranties. Any representation or warranty of the Borrower made in this Note or in any agreement,

statement or certificate given in writing pursuant hereto or in connection herewith, or in connection with the Purchase Agreement or

any Transaction Document, shall be false or misleading in any material respect when made.

3.5

Receiver or Trustee. The Borrower or any Subsidiary of the Borrower shall make an assignment for the benefit of creditors, or

apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such

a receiver or trustee shall otherwise be appointed.

3.6

Bankruptcy. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary,

for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any Subsidiary

of the Borrower and, in the case of involuntary proceedings, have not been dismissed within 61 days.

3.7

Delisting of Common Stock on the Trading Market. The Borrower shall fail to maintain the listing or quotation of the Common Stock

on Nasdaq Capital Market.

3.8

Liquidation. The Borrower commences any dissolution, liquidation, or winding up of Borrower or any substantial portion of its

business.

3.9

SEC Reporting Failure. The Borrower shall fail to be or remain current in the filing of all reports and other materials required

to be filed by the Borrower pursuant to Section 13(a) or 15(d) of the Exchange Act, including any failure to timely file any such report

(after giving effect to any applicable extension period pursuant to Rule 12b-25 under the Exchange Act), or the Borrower shall otherwise

cease to be subject to the reporting requirements of the Exchange Act.

ARTICLE

MISCELLANEOUS

4.1

Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege

hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude

other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative

to, and not exclusive of, any rights or remedies otherwise available.

4.2

Notices. All notices, offers, acceptance and any other acts under this Notice (except payment) shall be in writing, and shall

be sufficiently given if delivered to the addressees in person, by e-mail, by FedEx or similar receipted next day delivery, as follows:

Ito

the Borrower, to:

Aspire

Biopharma Holdings, Inc.

23150

Fashion Drive, Ste 232

Estero,

FL 33928

Att:

Kraig Higginson, Chief Executive Officer

Aspire

Biopharma Holdings, Inc.

23975

Park Sorrento, Suite 205

Calabasas,CA

91302

Email:

amir@neonc.com

Attention:

Amir Heshmatpour, President

with

a copy to:

Sichenzia

Ross Ference Carmel, LLP

1185

Avenue of Americas, 26th Floor

New

York, NY 10036

Att:

Arthur S. Marcus, Esq.

(which

shall not constitute notice)

Manatt,

Phelps & Phillips LLP

695

Town Center Drive, 14th Floor

to Holder:

Email:

Attention:

4.3

Amendments. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the

Holder. The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument as originally

executed, or if later amended or supplemented, then as so amended or supplemented.

4.4

Assignability. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit

of the Holder and its successors and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of

the Borrower hereunder may not be assigned, by operation of law or otherwise, in whole or in part, by the Borrower without the prior

signed written consent of the Holder, which consent may be withheld at the sole discretion of the Holder (any such assignment or transfer

shall be null and void if the Borrower does not obtain the prior signed written consent of the Holder). This Note or any of the severable

rights and obligations inuring to the benefit of or to be performed by Holder hereunder may be assigned by Holder to a third party, in

whole or in part, without the need to obtain the Borrower’s consent thereto. Each transferee of this Note must be an “accredited

investor” (as defined in Rule 501(a) of the Securities Act). Notwithstanding anything in this Note to the contrary, this Note may

be pledged as collateral in connection with a bona fide margin account or other lending arrangement.

4.5

Cost of Collection. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection,

including reasonable attorneys’ fees.

4.6

Governing Law. This Note shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard

to the principles of conflicts of law of any other jurisdiction.

4.7

Arbitration. Any disputes, claims, or controversies arising out of or relating to this Note, or the transactions, contemplated

thereby, or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability

of this Note to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration as provided for in the Purchase

Agreement. Either party to this Note may, without waiving any remedy under this Note, seek from any federal or state court sitting in

the State of Delaware any interim or provisional relief that is necessary to protect the rights or property of that party, pending the

establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid by and be the sole responsibility of

the Borrower, including but not limited to the Holder’s attorneys’ fees, and each arbitrator’s fees. The arbitrators’

decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrators’ decision and award

will be made and delivered as soon as reasonably possible and in any case within sixty days’ following the conclusion of the arbitration

hearing and shall be final and binding on the parties and may be entered by any court having jurisdiction thereof.

4.8

JURY TRIAL WAIVER. THE BORROWER AND THE HOLDER HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER

OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS NOTE.

4.9

Certain Amounts. Whenever pursuant to this Note the Borrower is required to pay an amount in excess of the outstanding Principal

Amount (or the portion thereof required to be paid at that time), the Borrower and the Holder agree that the actual damages to the Holder

from the receipt of cash payment on this Note may be difficult to determine and the amount to be so paid by the Borrower represents stipulated

damages and not a penalty and is intended to compensate the Holder in part for loss of the opportunity to convert this Note and to earn

a return from the sale of shares of Common Stock acquired upon conversion of this Note at a price in excess of the price paid for such

shares pursuant to this Note. The Borrower and the Holder hereby agree that such amount of stipulated damages is not plainly disproportionate

to the possible loss to the Holder from the receipt of a cash payment without the opportunity to convert this Note into shares of Common

Stock.

4.10

Remedies. The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder,

by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at

law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the

Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in

equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach

of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without

any bond or other security being required.

4.11

Usury. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing

usury, the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest

permitted under applicable law. The Borrower covenants (to the extent that it may lawfully do so) that it will not seek to claim or take

advantage of any law that would prohibit or forgive the Borrower from paying all or a portion of the principal or interest, if any, on

this Note.

signature page to follow **

WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer on the Issue Date.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

Name:

Title:

EXHIBIT

SECURED

CONVERTIBLE PROMISSORY-NOTE - NOTICE OF CONVERSION

The

undersigned hereby elects to convert $_____ amount of this Note (defined below) into that number of shares of Common Stock to be issued

pursuant to the conversion of this Note (“Common Stock”) as set forth below, of Aspire Biopharma Holdings, Inc. (the

“Borrower”), according to the conditions of the convertible promissory note of the Borrower dated as of August 6,

2026 (the “Note”), as of the date written below. No fee will be charged to the Holder for any conversion, except for

transfer taxes, if any.

Box

Checked as to applicable instructions:

☐

The

Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned

or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).

Name

of DTC Prime

Broker:

Account Number:

☐

The

undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth

below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or,

if additional space is necessary, on an attachment hereto:

[______]

e-mail:

[______]

Date

of Conversion:

_____

Applicable

Conversion Price:

$_____

Number

of Shares of Common Stock to be Issued Pursuant to Conversion of this Note:

_____

Amount

of Principal Balance Due remaining Under this Note after this conversion:

_____

[______]

By:

Name:

Title:

Date:

EX-99.1

Filename: ex99-1.htm · Sequence: 5

Exhibit 99.1

Aspire Biopharma Completes Acquisition of Dura

Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

●

Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise

●

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems

●

Augments revenue growth profile and diversifies

Aspire’s development and commercial portfolio with new high growth business

●

Expected to immediately improve path to profitability

ESTERO, FL / August 10, 2026 / Aspire Biopharma

Holdings, Inc. (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that

the Company has completed its previously announced acquisition (the “Acquisition”) of Dura Driver Control Systems

(“DCS”), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration

toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire’s ability

to deliver increased revenues, durable earnings and cash flow, driven by a new portfolio of product offerings in the large and growing

markets for vehicle and mobility control systems.

Pursuant to the terms of the SPA, Aspire has

acquired 100% of the issued and outstanding shares of DCS, and DCS has become a wholly owned subsidiary of the Company. Aspire

purchased these shares for approximately $30.0 million in cash.

Aspire also announced that, in connection

with the Acquisition of DCS, it entered into a $22.5 million senior secured revolving credit facility (the “New Revolving Facility”).

Aspire intends to use the borrowings under the New Revolving Facility and cash on hand, to fund the consideration payable for the Acquisition.

DCS CEO Hans Vorstenbosch will continue as CEO

of Aspire’s DCS subsidiary with the existing DCS management team under the leadership of Gregory J. Corona, the Chairman of Lakewood

& Company.

“Closing the DCS acquisition is a cash-flow-positive

milestone that structurally enhances Aspire’s valuation,” said Kraig Higginson, CEO and Chairperson of the Aspire’s Board.

“Absorbing DCS’s FY2025 financial footprint—exceeding $200 million in revenue and $22.3 million in Adjusted EBITDA1

in 2025—immediately elevates us to enterprise scale. This transaction captures immediate, high-volume

revenue streams to strengthen our capital flexibility and drive long-term shareholder value.”

Key Strategic & Operational Pillars

● Strong Financial Profile: For

the six months ended June 30, 2026 (unaudited) and twelve months ended December 31, 2025 (unaudited), DCS generated (a) revenue

of approximately $103.9 million and $209.5 million, respectively, (b) Adjusted EBITDA1 of approximately $10.5 million and

$22.3 million, respectively.

● Global Manufacturing Scale: Operates 11 global manufacturing

facilities strategically located across North America, Europe, and Asia.

● Blue Chip Customer Base Diversified portfolio of more

than 50 customers, highlighted by an average relationship longevity of 28 years with its top 10 OEM clients, supporting more than 150

vehicle platforms and 250 high-volume, global vehicle models.

● Extensive Intellectual Property: DCS maintains a proprietary

portfolio of over 275 distinct parts and more than 310 patents.

● Seasoned Management: The existing DCS leadership team

will be bolstered by automotive operating and investment professionals from Lakewood & Company, bringing more than 200 years of collective

automotive industry, OEM, tier-one supplier, and industrial sector expertise.

1Non-GAAP Financial Measure Notice: DCS

defines Adjusted EBITDA as earnings before interest expense, income tax, depreciation, and amortization, inclusive of specifically identified

adjustments. The Company believes Adjusted EBITDA provides useful supplemental information to investors regarding DCS’s operational

and financial performance. Adjusted EBITDA as presented herein may not be comparable to similarly titled measures reported by other companies.

Advisor

RBW Capital Partners LLC is acting as exclusive

financial advisor to the Company in connection with the acquisition. Any securities or brokerage services are offered through

Dawson James Securities, Inc.

About Dura Driver Control Systems

DCS is a leading designer and manufacturer of

highly engineered automotive and industrial systems that facilitate electronic driver control and support migration toward vehicle electrification,

safety, lightweighting, and sustainability. DCS maintains a strong powertrain agnostic product portfolio that includes mechatronic actuators,

human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates 11 manufacturing

facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending

sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve

effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s

delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning

both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory

Kevin McGrath

+1-646-418-7002

kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking

statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities

Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s

forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes,

beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or

other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words

“anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,”

“intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”

“project,” “should,” “will,” “would,” and similar expressions may identify forward-looking

statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent

our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent

events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events

or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required

under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any

subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially

different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ

include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction

of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays

in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results

for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect

the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug

candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the

development and commercialization of our drug candidates, and other risks and uncertainties set forth in “Risk Factors” in

our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific to the proposed

acquisition of DCS include, without limitation: the risk that due diligence, including the audit of DCS’s financial statements under

U.S. GAAP, may reveal information that adversely affects the terms or viability of the transaction; risks related to DCS’s business,

including its dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential

liabilities associated with DCS’s operations and intellectual property, the ability to successfully integrate DCS’s operations

following closing, and the risk that anticipated financial benefits from the acquisition may not be realized, including the risk that

the business operations and strategies of DCS and Aspire may diverge. In addition, statements that “we believe” and similar

statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of

the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may

be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review

of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly

upon these statements. All information in this press release is as of the date of this press release. The information contained in any

website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 6

Binary file (5826 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 23

v3.26.1

Cover

Aug. 06, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-41293

Entity Registrant Name

Aspire

Biopharma Holdings, Inc.

Entity Central Index Key

0001847345

Entity Tax Identification Number

33-3467744

Entity Incorporation, State or Country Code

Entity Address, Address Line One

23150

Fashion Drive

Entity Address, Address Line Two

Suite 232

Entity Address, City or Town

Estero

Entity Address, State or Province

Entity Address, Postal Zip Code

33928

City Area Code

(908)

Local Phone Number

987-3002

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common stock, par value $0.0001 per share

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

ASBP

Security Exchange Name

NASDAQ

Warrants, each exercisable for one share of common stock

Title of 12(b) Security

Warrants,

each exercisable for one share of common stock

Trading Symbol

ASBPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_WarrantsEachExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: